- Home
- PHIO vs AEI Comparison
PHIO vs AEI Comparison
Compare PHIO & AEI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHIO
- AEI
- Stock Information
- Founded
- PHIO 2011
- AEI 2014
- Country
- PHIO United States
- AEI United States
- Employees
- PHIO N/A
- AEI N/A
- Industry
- PHIO Biotechnology: Pharmaceutical Preparations
- AEI Building operators
- Sector
- PHIO Health Care
- AEI Real Estate
- Exchange
- PHIO Nasdaq
- AEI Nasdaq
- Market Cap
- PHIO 12.1M
- AEI 13.6M
- IPO Year
- PHIO N/A
- AEI N/A
- Fundamental
- Price
- PHIO $2.04
- AEI $1.66
- Analyst Decision
- PHIO Strong Buy
- AEI
- Analyst Count
- PHIO 3
- AEI 0
- Target Price
- PHIO $10.67
- AEI N/A
- AVG Volume (30 Days)
- PHIO 139.7K
- AEI 1.0M
- Earning Date
- PHIO 08-14-2025
- AEI 08-14-2025
- Dividend Yield
- PHIO N/A
- AEI N/A
- EPS Growth
- PHIO N/A
- AEI N/A
- EPS
- PHIO N/A
- AEI N/A
- Revenue
- PHIO N/A
- AEI $16,069,911.00
- Revenue This Year
- PHIO N/A
- AEI N/A
- Revenue Next Year
- PHIO N/A
- AEI N/A
- P/E Ratio
- PHIO N/A
- AEI N/A
- Revenue Growth
- PHIO N/A
- AEI 74.28
- 52 Week Low
- PHIO $0.97
- AEI $0.70
- 52 Week High
- PHIO $9.79
- AEI $2.61
- Technical
- Relative Strength Index (RSI)
- PHIO 42.33
- AEI 58.32
- Support Level
- PHIO $1.96
- AEI $1.35
- Resistance Level
- PHIO $2.13
- AEI $2.22
- Average True Range (ATR)
- PHIO 0.10
- AEI 0.22
- MACD
- PHIO 0.01
- AEI 0.05
- Stochastic Oscillator
- PHIO 44.83
- AEI 46.67
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
About AEI Alset Inc. (TX)
Alset Inc is a diversified holding company engaged through its subsidiaries in the development of EHome communities and other real estate, financial services, digital transformation technologies, biohealth activities, and consumer products with operations in the United States, Singapore, Hong Kong, Australia, and South Korea. The Company operates in four business segments: real estate, digital transformation technology, Biohealth, and other business activities, and it derives a majority of its revenue from the Real Estate segment.